DOCSLIB.ORG

Stem-Cell-Children Executive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Comparative Effectiveness Review Number 48 Effective Health Care Program Hematopoietic Stem-Cell Transplantation in the Pediatric Population Executive Summary Background Effective Health Care Program Hematopoietic stem-cell transplantation The Effective Health Care Program (HSCT) refers to a procedure in which was initiated in 2005 to provide hematopoietic progenitor cells, including valid evidence about the comparative repopulating stem cells, are infused effectiveness of different medical to restore bone marrow function in interventions. The object is to help patients.1,2,3 HSCT is categorized by the consumers, health care providers, source of the stem cells, with its role in and others in making informed pediatric diseases dependent in part on choices among treatment alternatives. the indication for which it is being used.4 Through its Comparative Effectiveness Autologous transplants involve harvesting Reviews, the program supports the patient’s own blood stem cells and then systematic appraisals of existing returning them, typically after the patient scientific evidence regarding has received doses of chemotherapy that treatments for high-priority health are myeloablative.1,2 Allogeneic HSCT conditions. It also promotes and uses stem cells from a donor who is generates new scientific evidence by either matched or unmatched on human identifying gaps in existing scientific leukocyte antigen (HLA) and either evidence and supporting new research. related or unrelated; in malignant diseases, The program puts special emphasis it exploits a graft-versus-tumor effect.5,6 on translating findings into a variety In the pediatric population, HSCT is of useful formats for different used to treat a wide variety of diseases, stakeholders, including consumers. both malignant and nonmalignant.7 For The full report and this summary are many of these diseases, HSCT is a well- available at www.effectivehealthcare. established treatment. For example, ahrq.gov/reports/final.cfm. the literature on the use of HSCT in hematologic malignancies is robust, including randomized controlled trials that date back 20 years, and its practice is supported by evidence-based guidelines. evidence consists of case series and case For many less common diseases—for reports, it is sufficient to demonstrate example, the primary immunodeficiencies improved outcomes, supporting use of and hemoglobinopathies—although the HSCT. Effective Health Care 1 The success of treating many of the pediatric diseases Key Question 3. For pediatric patients with inherited with HSCT has resulted in an increased number of metabolic diseases, what is the comparative effectiveness long-term survivors. As improvements in survival have of HSCT, enzyme-replacement therapy (ERT), and been achieved, there is greater concern about long- substrate reduction with iminosugars regarding overall term effects and how adverse effects (e.g., graft-vs.- survival, cure, long-term consequences of HSCT, and host disease, opportunistic infections, future infertility, quality of life? developmental delay, and secondary malignancies) might 7,8,9,10 Key Question 4. For pediatric patients with inherited be mitigated. The Key Questions for this review metabolic diseases, what are the comparative harms of compared benefits and harms of HSCT and conventional HSCT, ERT, and substrate reduction with iminosugars therapy for pediatric diseases. regarding adverse effects of treatment, long-term consequences of HSCT, and impaired quality of life? Objectives Key Question 5. For pediatric patients with autoimmune Key Questions addressed in this report are split into diseases, what is the comparative effectiveness of HSCT, three groups of two questions each. They pertain to immunosuppressants, targeted biologic therapies, and low- malignant solid tumors, inherited metabolic diseases, and dose chemotherapy regarding overall survival, cure, and autoimmune diseases. remission? Key Question 1. For pediatric patients with malignant Key Question 6. For pediatric patients with autoimmune solid tumors, what is the comparative effectiveness of diseases, what are the comparative harms of HSCT, HSCT and conventional chemotherapy regarding overall immunosuppressants, targeted biologic therapies, and low- survival, long-term consequences of HSCT, and quality of dose chemotherapy regarding adverse effects of treatment, life? long-term consequences of HSCT, and impaired quality of Key Question 2. For pediatric patients with malignant life? solid tumors, what are the comparative harms of HSCT and conventional chemotherapy regarding adverse effects Analytic Framework of treatment, long-term consequences of HSCT, and Analytic frameworks are detailed in Figures A, B, and C. impaired quality of life? Figure A. Analytic framework for HSCT for pediatric malignant solid tumors KQ 1 Treatment, therapy, or intervention -HSCT Final health outcomes Intermediate Outcomes Pediatric KQ 1 KQ 1 • Overall survival malignant solid • Recurrence-free survival • Long-term tumors • Progression-free survival consequences of HSCT • QOL KQ 2 Adverse effects of treatment • Immunosuppression (e.g., opportunistic infection) • Specific organ injury HSCT = hematopoietic stem-cell transplantation; KQ = Key Question; QOL = quality of life 2 Figure B. Analytic framework for HSCT for pediatric inherited metabolic diseases KQ 3 Treatment, therapy, or intervention -HSCT Intermediate Outcomes Final health outcomes Pediatric KQ 3 • Stable source of endogenous KQ 3 • Survival inherited metabolic enzyme • Cure • Long-term diseases • Stabilization or slowed progression of neurocognitive consequences of decline HSCT KQ 4 • QOL Adverse effects of treatment • GVHD • Immunosuppression (e.g., opportunistic infection) • Specific organ injury GVHD = graft-versus-host disease; HSCT = hematopoietic stem-cell transplantation; KQ = Key Question; QOL = quality of life Figure C. Analytic framework for HSCT for pediatric autoimmune diseases KQ 5 Treatment, therapy, or intervention -HSCT Final health outcomes Intermediate Outcomes • Remission Pediatric KQ 5 Slowing of the progression of or KQ 5 inherited metabolic • Overall survival improvement in organ damage • Cure diseases secondary to the autoimmune • Long-term disease consequences of HSCT KQ 6 • QOL Adverse effects of treatment • GVHD • Immunosuppression (e.g., opportunistic infection) • Specific organ injury GVHD = graft-versus-host disease; HSCT = hematopoietic stem-cell transplantation; KQ = Key Question; QOL = quality of life 3 Methods clinical practice was less established, so that systematic review of the literature would be more likely to provide Topic Refinement new insight to inform the field (Table B). This report comprises a set of narrative reviews and The final categorization of indications for the narrative systematic reviews that were defined during the topic reviews was determined in an iterative process. refinement phase of the project. Topic refinement Information sources for the narrative reviews were not also outlined the frameworks and PICOTS (patients, identified by a systematic search of the literature. Rather, interventions, comparator, outcome, timing, setting) that the EPC relied on recently published reviews of pediatric were posted for public comments and incorporated into the transplantation studies and publicly available sources, such final version. Following completion of the topic refinement as the National Guidelines Clearinghouse and the National phase, a Technical Expert Panel (TEP) was formed. The Cancer Institute Physicians Data Query (PDQ) Web site, TEP included original Key Informant (KI) panel members to develop an initial list of diseases for discussion with the and clinical experts not previously involved. The TEP KI panel. The EPC subsequently reexamined the lists and provided consultation on the development of the protocol compared them with existing evidence in the context of and evidence tables for the review. In particular, the TEP the KI discussions. A final list of indications for narrative provided advice on appropriate clinical outcome data reviews compiled by the EPC was posted for public to compile for both benefits and harms. Ad hoc clinical comment. Neuroblastoma, germ cell tumors, and central questions were also addressed to the TEP. nervous system embryonal tumors are covered in both narrative and systematic reviews. They are distinguished Narrative Reviews in each by the specific indication and the type of transplant The narrative review approach to the conditions presented procedure, as shown in Tables A and B. in Table A was based on the recognition that there exists Systematic Reviews a substantial body of evidence from 20 years or more of transplantation research and experience that has been Table B shows the indications that were systematically codified into published guidelines and reviews. Thus, reviewed. Neuroblastoma, germ cell tumors, and central systematic review of the evidence for these diseases would nervous system embryonal tumors are covered in both not be expected to offer new insights or information. narrative and systematic reviews. They are distinguished In contrast, the Evidence-based Practice Center (EPC) in each by the specific indication and the type of transplant recognized that there were a number of diseases for which procedure, as shown in Tables A and B. evidence of benefits and harms was less clear or for which Table A. Pediatric HSCT indications to be addressed with narrative review Type Disease Indication(s) Transplant Type MH Acute lymphoblastic
Recommended publications
  • Café Au Lait Spots As a Marker of Neuropaediatric Diseases

    Café Au Lait Spots As a Marker of Neuropaediatric Diseases

    Mini Review Open Access J Neurol Neurosurg Volume 3 Issue 5 - May 2017 DOI: 10.19080/OAJNN.2017.03.555622 Copyright © All rights are reserved by Francisco Carratalá-Marco Café Au Lait Spots as a Marker of Neuropaediatric Diseases Francisco Carratalá-Marco1*, Rosa María Ruiz-Miralles2, Patricia Andreo-Lillo1, Julia Dolores Miralles-Botella3, Lorena Pastor-Ferrándiz1 and Mercedes Juste-Ruiz2 1Neuropaediatric Unit, University Hospital of San Juan de Alicante, Spain 2Paediatric Department, University Hospital of San Juan de Alicante, Spain 3Dermatology Department, University Hospital of San Juan de Alicante, Spain Submission: March 22, 2017; Published: May 10, 2017 *Corresponding author: Francisco Carratalá-Marco, Neuropaediatric Unit, University Hospital of San Juan de Alicante, Spain, Tel: ; Email: Abstract Introduction: want to know in which The measure,Café au lait the spots presence (CALS) of isolated are shown CALS in representsthe normal a population risk factor forwithout neurological pathological disease. significance, although they could also be criteria for some neurologic syndromes. Unspecific association with general neurologic illnesses has been less frequently described. We Patients and methods: We set up an observational transversal study of cases, patients admitted for neuropaediatric reasons (NPP; n=49) excluding all the patients suffering from neurologic illnesses associated to CALS, and controls, a hospital simultaneously admitted pediatric population for non-neurologic causes (CP; n=101) since October 2012 to January 2013. The data were collected from the clinical reports at admission, and then analyzed by SPSS 22.0 statistical package, and the Stat Calc module of EpiInfo 7.0, following the ethics current rules of the institution for observational studies.
  • EFFECTIVE NEBRASKA DEPARTMENT of 01/01/2017 HEALTH and HUMAN SERVICES 173 NAC 1 I TITLE 173 COMMUNICABLE DISEASES CHAPTER 1

    EFFECTIVE NEBRASKA DEPARTMENT of 01/01/2017 HEALTH and HUMAN SERVICES 173 NAC 1 I TITLE 173 COMMUNICABLE DISEASES CHAPTER 1

    EFFECTIVE NEBRASKA DEPARTMENT OF 01/01/2017 HEALTH AND HUMAN SERVICES 173 NAC 1 TITLE 173 COMMUNICABLE DISEASES CHAPTER 1 REPORTING AND CONTROL OF COMMUNICABLE DISEASES TABLE OF CONTENTS SECTION SUBJECT PAGE 1-001 SCOPE AND AUTHORITY 1 1-002 DEFINITIONS 1 1-003 WHO MUST REPORT 2 1-003.01 Healthcare Providers (Physicians and Hospitals) 2 1-003.01A Reporting by PA’s and APRN’s 2 1-003.01B Reporting by Laboratories in lieu of Physicians 3 1-003.01C Reporting by Healthcare Facilities in lieu of Physicians for 3 Healthcare Associated Infections (HAIs) 1-003.02 Laboratories 3 1-003.02A Electronic Ordering of Laboratory Tests 3 1-004 REPORTABLE DISEASES, POISONINGS, AND ORGANISMS: 3 LISTS AND FREQUENCY OF REPORTS 1-004.01 Immediate Reports 4 1-004.01A List of Diseases, Poisonings, and Organisms 4 1-004.01B Clusters, Outbreaks, or Unusual Events, Including Possible 5 Bioterroristic Attacks 1-004.02 Reports Within Seven Days – List of Reportable Diseases, 5 Poisonings, and Organisms 1-004.03 Reporting of Antimicrobial Susceptibility 8 1-004.04 New or Emerging Diseases and Other Syndromes and Exposures – 8 Reporting and Submissions 1-004.04A Criteria 8 1-004.04B Surveillance Mechanism 8 1-004.05 Sexually Transmitted Diseases 9 1-004.06 Healthcare Associated Infections 9 1-005 METHODS OF REPORTING 9 1-005.01 Health Care Providers 9 1-005.01A Immediate Reports of Diseases, Poisonings, and Organisms 9 1-005.01B Immediate Reports of Clusters, Outbreaks, or Unusual Events, 9 Including Possible Bioterroristic Attacks i EFFECTIVE NEBRASKA DEPARTMENT OF
  • Neuroradiologic Findings in Fucosidosis, a Rare Lysosomal Storage Disease

    Neuroradiologic Findings in Fucosidosis, a Rare Lysosomal Storage Disease

    Neuroradiologic Findings in Fucosidosis, a Rare Lysosomal Storage Disease James M. Provenzale, Daniel P. Barboriak, and Katherine Sims Summary: Fucosidosis is a rare lysosomal storage disorder with vacuolated secondary lysosomes containing some fine the clinical features of mental retardation, cardiomegaly, dysos- fibrillar material and lamellated membrane structures. tosis multiplex, progressive neurologic deterioration, and early A magnetic resonance (MR) examination at the age of death. The neuroradiologic findings in two patients are reported, 10 years showed confluent regions of hyperintense signal and include abnormalities within the globus pallidus (both pa- on T2-weighted images in the periventricular regions, tients) and periventricular white matter (one patient). most prominent surrounding the atria of the lateral ventri- cles. Hyperintense signal was noted in the globus pallidus Index terms: Brain, metabolism; Degenerative disease, Pediatric on T1-weighted images, with corresponding hypointense neuroradiology signal on T2-weighted images (Fig 1). Fucosidosis is a rare metabolic disorder caused by decreased amounts of the enzyme Case 2 a-L-fucosidase, which results in the accumula- A 2-year-old boy was examined for speech delay and tion of fucose-rich storage products within psychomotor retardation. He was born at term after a many organs, including the brain. Patients with normal pregnancy, and appropriate development oc- this disorder usually have delayed intellectual curred during the first year of life. However, by age 2 years, and motor development, and often die within the patient had not developed speech, exhibited autistic the first decade of life. Computed tomographic behavior, and performed motor tasks poorly. Physical ex- (CT) findings have been reported in a few cases amination findings included coarsened facial features, nar- (1, 2).
  • Fusion of Multiple Heterogeneous Networks for Predicting Circrna

    Fusion of Multiple Heterogeneous Networks for Predicting Circrna

    www.nature.com/scientificreports OPEN Fusion of multiple heterogeneous networks for predicting circRNA- disease associations Received: 22 January 2019 Lei Deng1, Wei Zhang1, Yechuan Shi1 & Yongjun Tang2 Accepted: 18 June 2019 Circular RNAs (circRNAs) are a newly identifed type of non-coding RNA (ncRNA) that plays crucial roles Published: xx xx xxxx in many cellular processes and human diseases, and are potential disease biomarkers and therapeutic targets in human diseases. However, experimentally verifed circRNA-disease associations are very rare. Hence, developing an accurate and efcient method to predict the association between circRNA and disease may be benefcial to disease prevention, diagnosis, and treatment. Here, we propose a computational method named KATZCPDA, which is based on the KATZ method and the integrations among circRNAs, proteins, and diseases to predict circRNA-disease associations. KATZCPDA not only verifes existing circRNA-disease associations but also predicts unknown associations. As demonstrated by leave-one-out and 10-fold cross-validation, KATZCPDA achieves AUC values of 0.959 and 0.958, respectively. The performance of KATZCPDA was substantially higher than those of previously developed network-based methods. To further demonstrate the efectiveness of KATZCPDA, we apply KATZCPDA to predict the associated circRNAs of Colorectal cancer, glioma, breast cancer, and Tuberculosis. The results illustrated that the predicted circRNA-disease associations could rank the top 10 of the experimentally verifed associations. Circular RNA (circRNA) is a class of non-coding RNA recently discovered. Unlike linear RNA, circRNA forms a continuous cycle of covalent closures and is highly represented in the eukaryotic transcriptome. Previous research has found thousands of prototype circRNAs in human, mouse and nematode cells1–4.
  • Study Guide Medical Terminology by Thea Liza Batan About the Author

    Study Guide Medical Terminology by Thea Liza Batan About the Author

    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
  • Eye Disease 1 Eye Disease

    Eye Disease 1 Eye Disease

    Eye disease 1 Eye disease Eye disease Classification and external resources [1] MeSH D005128 This is a partial list of human eye diseases and disorders. The World Health Organisation publishes a classification of known diseases and injuries called the International Statistical Classification of Diseases and Related Health Problems or ICD-10. This list uses that classification. H00-H59 Diseases of the eye and adnexa H00-H06 Disorders of eyelid, lacrimal system and orbit • (H00.0) Hordeolum ("stye" or "sty") — a bacterial infection of sebaceous glands of eyelashes • (H00.1) Chalazion — a cyst in the eyelid (usually upper eyelid) • (H01.0) Blepharitis — inflammation of eyelids and eyelashes; characterized by white flaky skin near the eyelashes • (H02.0) Entropion and trichiasis • (H02.1) Ectropion • (H02.2) Lagophthalmos • (H02.3) Blepharochalasis • (H02.4) Ptosis • (H02.6) Xanthelasma of eyelid • (H03.0*) Parasitic infestation of eyelid in diseases classified elsewhere • Dermatitis of eyelid due to Demodex species ( B88.0+ ) • Parasitic infestation of eyelid in: • leishmaniasis ( B55.-+ ) • loiasis ( B74.3+ ) • onchocerciasis ( B73+ ) • phthiriasis ( B85.3+ ) • (H03.1*) Involvement of eyelid in other infectious diseases classified elsewhere • Involvement of eyelid in: • herpesviral (herpes simplex) infection ( B00.5+ ) • leprosy ( A30.-+ ) • molluscum contagiosum ( B08.1+ ) • tuberculosis ( A18.4+ ) • yaws ( A66.-+ ) • zoster ( B02.3+ ) • (H03.8*) Involvement of eyelid in other diseases classified elsewhere • Involvement of eyelid in impetigo
  • DIAGNOSIS and TREATMENT of BRUCELLOSIS (Undulant Fever)

    DIAGNOSIS and TREATMENT of BRUCELLOSIS (Undulant Fever)

    DIAGNOSIS AND TREATMENT OF BRUCELLOSIS (Undulant Fever) CHARLES L. HARTSOCK, M.D. Not only the treatment but also the diagnosis of undulant fever are far from being satisfactory, although many types of therapy are being tried and critically evaluated. Because of the tremendous scope of the disease, frequent discussions and reappraisals of our ideas about bru- cellosis will be absolutely essential for some time. Some physicians more or less disregard brucellosis and even scoff at the chronic phase of this new intruder in the realm of human disease. Others are overenthusi- astic and attempt to explain many vague and indefinite problems upon the basis of chronic brucellosis without sufficient evidence. Still other physicians have lost their original enthusiasm and have reverted to the first viewpoint, probably because of the great difficulty in coping with the caprices and vagaries of this disease and the marked uncertainties in diagnosis and treatment. Even though this disease is extremely protean and remarkably bizarre in its manifestations, it is a disease of known causative organism to which the generic term of brucella has been given. The original infection in man was traced to the drinking of goat's milk on the Island of Malta, and for many years this disease was known as Malta fever. Because of the undulating character of the fever with a tendency for remissions and recurrences, it was later called undulant fever which proved to be a very poor description of the febrile reaction in many instances. Brucellosis is the more specific term derived from the organism causing the disease. Three strains of the brucella organism have been isolated and named for their respective hosts: b.
  • International Requisition Form

    International Requisition Form

    PleasePlease place place collection collection kit kit INTERNATIONAL barcode here. REQUISITION FORM barcode here. REQUISITION FORM 123456-2-X PLEASE COMPLETE ALL FIELDS. REQUISITION FORMS SUBMITTED WITH MISSING INFORMATION MAY CAUSE A DELAY IN TURNAROUND TIME OF THE TEST. PLEASE COMPLETE ALL FIELDS. REQUISITION FORMS SUBMITTED WITH MISSING INFORMATION MAY CAUSE A DELAY IN TURNAROUND TIME OF THE TEST. PATIENT INFORMATION ORDERING CLINICIAN INFORMATION PATIENT NAME (LAST, FIRST) NAME OF ORGANIZATION 1 PatIENT INFORmatION (Must be completed in English) 2 ORDERING CLINICIAN (Must be completed in English) DATE OF BIRTH (MM/DD/YYYY) Organization (Clinic, Hospital, or Lab): Patient Name (Last, First): ADDRESS TELEPHONE CITYPatient DOB (DD/MM/YYYY): STATE ZIP CODE ORDERINGLIMS-ID: CLINICIAN TELEPHONE EMAIL Patient Street Address: Telephone: I would like to receive emails about my test from Natera Y N City: Country: Ordering Clinician: PATIENT MALE OR FEMALE? M-V26.34 F-V26.31 PATIENT PREGNANT? Y-V22.1 N DATE OF SAMPLE COLLECTION (MM/DD/YY):_____________________________ Telephone: Email: PAYMENT PLEASEPatient CHECK male orONE: female: M F BILL INSURANCE BILL CLINIC BILL CLINIC/CA Prenatal SELF-PAY Patient pregnant? Program YPDC N INSURANCE COMPANY (Please enclose a photocopy (front and CLINICIAN INFORMED CONSENT MEMBERDate of ID sample collectionSUBSCRIBER (DD/MM/YYYY): NAME (if different than patient) back) or all relevant insurance cards) If you would like the results of this case to be sent to an additional FAX fax number other than what is indicated on your setup form, please IF SELF-PAY, CHECK CARD TYPE: VISA MASTER CARD AMEX DISCOVER provide the fax number.
  • European Conference on Rare Diseases

    European Conference on Rare Diseases

    EUROPEAN CONFERENCE ON RARE DISEASES Luxembourg 21-22 June 2005 EUROPEAN CONFERENCE ON RARE DISEASES Copyright 2005 © Eurordis For more information: www.eurordis.org Webcast of the conference and abstracts: www.rare-luxembourg2005.org TABLE OF CONTENT_3 ------------------------------------------------- ACKNOWLEDGEMENTS AND CREDITS A specialised clinic for Rare Diseases : the RD TABLE OF CONTENTS Outpatient’s Clinic (RDOC) in Italy …………… 48 ------------------------------------------------- ------------------------------------------------- 4 / RARE, BUT EXISTING The organisers particularly wish to thank ACKNOWLEDGEMENTS AND CREDITS 4.1 No code, no name, no existence …………… 49 ------------------------------------------------- the following persons/organisations/companies 4.2 Why do we need to code rare diseases? … 50 PROGRAMME COMMITTEE for their role : ------------------------------------------------- Members of the Programme Committee ……… 6 5 / RESEARCH AND CARE Conference Programme …………………………… 7 …… HER ROYAL HIGHNESS THE GRAND DUCHESS OF LUXEMBOURG Key features of the conference …………………… 12 5.1 Research for Rare Diseases in the EU 54 • Participants ……………………………………… 12 5.2 Fighting the fragmentation of research …… 55 A multi-disciplinary approach ………………… 55 THE EUROPEAN COMMISSION Funding of the conference ……………………… 14 Transfer of academic research towards • ------------------------------------------------- industrial development ………………………… 60 THE GOVERNEMENT OF LUXEMBOURG Speakers ……………………………………………… 16 Strengthening cooperation between academia
  • Childhood Dementia Initiative

    Childhood Dementia Initiative

    Childhood Dementia in Australia: quantifying the burden on patients, carers, the healthcare system and our society Prepared by: Dominic Tilden, Madeline Valeri and Magda Ellis THEMA Consulting Pty Ltd www.thema.net Prepared for: Childhood Dementia Initiative www.childhooddementia.org THEMA Consulting Report (2020). Childhood Dementia in Australia: quantifying the burden on patients, carers, the healthcare system and our society. www.childhooddementia.org/burdenstudy Released on the 18th November 2020 Sydney, Australia. © Childhood Dementia Initiative 2020 Website address for further details. www.childhooddementia.org KEY POINTS : Childhood dementia is a recognised, albeit little known group of disorders, comprised of more than 70 individual genetic conditions. : Childhooddementiadisordersareprogressiveanddevastatinginnatureandposeasignificantlycomplex medicalchallenge,withpatientstypicallyrelyingonfulltimesupportivecareandextensivehealthcare services in the mid-later stages of the disease. : ThisstudydemonstratesforthefirsttimetheburdenassociatedwithchildhooddementiainAustralia, the tremendous negative impact it has on affected children, families and the community, and the resulting economic costs. : Effective therapeutic intervention remains an unmet clinical need for the vast majority of childhood dementia disorders. : It is estimated that the collective incidence of disorders that cause childhood dementia is 36 per 100,000 live births. This equates to 129 births in Australia each year. : In 2021, it is estimated there will be 2273 Australians
  • Diseases Transmitted Through the Food Supply

    Diseases Transmitted Through the Food Supply

    DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Diseases Transmitted through the Food Supply AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human ­ Services (HHS). ­ ACTION: Notice of annual update of list of infectious and communicable diseases that are ­ transmitted through handling the food supply and the methods by which such diseases are ­ transmitted. ­ SUMMARY: Section 103 (d) of the Americans with Disabilities Act of 1990, Public Law 101–336, ­ requires the Secretary to publish a list of infectious and communicable diseases that are ­ transmitted through handling the food supply and to review and update the list annually. The ­ Centers for Disease Control and Prevention (CDC) published a final list on August 16, 1991 (56 ­ FR40897) and updates on September 8, 1992 (57 FR 40917); January 13, 1994 (59 FR 1949); ­ August 15, 1996 (61 FR 42426); September 22, 1997 (62 FR 49518–9); September 15, 1998 (63 ­ FR 49359); September 21, 1999 (64 FR 51127); September 27, 2000 (65 FR 58088); September ­ 10, 2001 (66 FR 47030); September 27, 2002 (67 FR 61109); September 26, 2006 (71 FR 56152); ­ November 17, 2008 (73 FR 67871); and November 29, 2009 (74 FR 61151). The final list has ­ been reviewed in light of new information and has been revised as set forth below. ­ DATES: Effective Date: January 31, 2014. ­ FOR FURTHER INFORMATION CONTACT: ­ Dr. Art Liang, Division of Foodborne Waterborne and Environment Diseases, National Center for ­ Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), ­ 1600 Clifton Road, NE., Mailstop G–24, Atlanta, Georgia 30333.
  • Part 3: European Commission Activities in the Field of Rare Diseases

    Part 3: European Commission Activities in the Field of Rare Diseases

    2014 REPORT ON THE STATE OF THE ART OF RARE DISEASE ACTIVITIES IN EUROPE PART III: EUROPEAN COMMISSION ACTIVITIES IN THE FIELD OF RARE DISEASES This work was financed by the EUCERD Joint Action: Working for Rare Diseases N° 2011 22 01 2014 Report on the State of the Art of Rare Disease Activities in Europe – Part III: European Commission activities in the field of rare diseases This document has been produced by the Scientific Secretariat of the European Union Committee of Experts on Rare Diseases (EUCERD) Joint Action through the EUCERD Joint Action: Working for Rare Diseases (N° 2011 22 01, Coordinator: Kate Bushby, University of Newcastle, United Kingdom), within the European Union’s Second Programme of Community Action in the Field of Health. The European Union Committee of Experts on Rare Diseases (EUCERD) was established in 2009 and its mandate ended in 2013. It is replaced from 2014 by the Commission Expert Group on Rare Diseases. The EUCERD Joint Action continues to support the activities of the new Expert Group until 2015. More information on the activities of the former European Union Committee of Experts on Rare Diseases and the EUCERD Joint Action can be found at www.eucerd.eu. Disclaimer: The findings and conclusions in this report are those of the contributors and validating authorities, who are responsible for the contents; the findings and conclusions do not necessarily represent the views of the European Commission or national health authorities in Europe. Therefore, no statement in this report should be construed as an official position of the European Commission or a national health authority.